Suchergebnisse - "Drug Costs statistics & numerical data"
-
1
Autoren: et al.
Schlagwörter: Aged, 80 and over, Drug Costs/statistics & numerical data, Education, Pharmacy, Continuing, Female, Humans, Male, Nursing Homes/legislation & jurisprudence, Nursing Homes/statistics & numerical data, Pharmacy Service, Hospital/economics, Hospital/methods, Physician's Practice Patterns, Practice Guidelines as Topic, Program Evaluation, Retrospective Studies, Switzerland
Relation: Pharmacy World and Science; 1573-739X[electronic]; https://iris.unil.ch/handle/iris/233571; serval:BIB_E3EA8B3DFE4A; 000264536000006
-
2
Autoren: et al.
Quelle: Health Policy. 122:1012-1017
Schlagwörter: Prescription Drugs, Drug Costs/statistics & numerical data, Developed Countries, 1. No poverty, Drug Costs, Insurance Coverage, United States, 3. Good health, Health Expenditures/statistics & numerical data, 03 medical and health sciences, 0302 clinical medicine, Universal Health Insurance, Prescription Drugs/economics, Humans, Health Expenditures
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/30041827
https://research-portal.uu.nl/en/publications/2a4f9ca1-576e-49da-bf3c-8ae4664172e7
https://doi.org/10.1016/j.healthpol.2018.07.005
https://ideas.repec.org/a/eee/hepoli/v122y2018i9p1012-1017.html
https://www.sciencedirect.com/science/article/pii/S016885101830246X
https://www.ncbi.nlm.nih.gov/pubmed/30041827
https://www.cabdirect.org/cabdirect/abstract/20193013146
http://europepmc.org/article/MED/30041827
https://pubmed.ncbi.nlm.nih.gov/30041827/ -
3
Autoren: Morgan, Steven G.
Quelle: Medical Care, 2005 Oct 01. 43(10), 996-1008.
Zugangs-URL: https://www.jstor.org/stable/4640907
-
4
Autoren:
Quelle: Canadian Medical Association Journal. 189:E794-E799
Schlagwörter: Canada, Prescription Drugs, Primary Health Care, Drug Costs/statistics & numerical data, Developed Countries, Australia, 1. No poverty, Primary Health Care/organization & administration, Drug Costs, 3. Good health, Health Expenditures/statistics & numerical data, Europe, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Universal Health Insurance, Prescription Drugs/economics, Health Expenditures, Universal Health Insurance/statistics & numerical data, New Zealand
-
5
Autoren:
Weitere Verfasser:
Schlagwörter: Hipoglucemiantes/economía, Drug Costs/statistics & numerical data, Análisis retrospectivo, Retrospective analysis, Costos de los Medicamentos/estadística & datos numéricos, 615 - Farmacología y terapéutica [610 - Medicina y salud], Gastos en Salud/tendencias, Consumo de medicamentos, Medication consumption, Hypoglycemic agents, Hypoglycemic Agents/economics, Hipoglucemiantes, Diabetes Mellitus, Health Expenditures/trends
Dateibeschreibung: 234 páginas; application/pdf
Zugangs-URL: https://repositorio.unal.edu.co/handle/unal/86407
-
6
Autoren:
Weitere Verfasser:
Schlagwörter: 610 - Medicina y salud::615 - Farmacología y terapéutica, Gastos en Salud/tendencias, Hipoglucemiantes/economía, Costos de los Medicamentos/estadística & datos numéricos, Health Expenditures/trends, Hypoglycemic Agents/economics, Drug Costs/statistics & numerical data, Hipoglucemiantes, Análisis retrospectivo, Consumo de medicamentos, Diabetes Mellitus, Hypoglycemic agents, Retrospective analysis, Medication consumption
Geographisches Schlagwort: Colombia, http://vocab.getty.edu/page/tgn/1000050
Time: 2019-2023
Dateibeschreibung: 234 páginas; application/pdf
Relation: Bireme; Arredondo, A., & Aviles, R. (2015). Costs and epidemiological changes of chronic diseases: implications and challenges for health systems. PloS one, 10(3), e0118611.; Briggs, A. D., Wolstenholme, J., Blakely, T., & Scarborough, P. (2016). Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. Population health metrics, 14(1), 1-12.; Caro Dougnac, D. (2014). Impacto económico de las enfermedades crónicas; Álvarez, J. S. (2012). Evaluación económica de medicamentos y tecnologías sanitarias. Madrid: Springer.; World Health Organization. (2022). Noncommunicable diseases: progress monitor 2022.; Cepal, N. U. (2018). Agenda 2030 y los Objetivos de Desarrollo Sostenible: una oportunidad para América Latina y el Caribe.; de Souza Cazarim, M., de Oliveira Gonçalves, A. C., Pereira, L. R. L., & de Oliveira Baldoni, A. (2018). Economic Evaluations in Health from the Perspective of the Costs Associated with Diabetes Mellitus Treatment. Diabetes and Its Complications, 165.; Yach, D., Stuckler, D., & Brownell, K. D. (2006). Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nature medicine, 12(1), 62-66.; O’Connell, J. M., & Manson, S. M. (2019). Understanding the economic costs of diabetes and prediabetes and what we may learn about reducing the health and economic burden of these conditions. Diabetes Care, 42(9), 1609.; Fondo Colombiano de Enfermedades de Alto Costo, Cuenta de Alto Costo (CAC). Situación de la enfermedad renal crónica, la hipertensión arterial, y la diabetes mellitus en Colombia 2022; Bogotá, D. C. 2023.Se prohíbe la reproducción total o parcial de este libro sin autorización escrita de la Cuenta de Alto Costo.; Caro Dougnac, D. (2014). Impacto económico de las enfermedades crónicas.; Willems, R., Pil, L., Lambrinou, C. P., Kivelä, J., Wikström, K., Gonzalez-Gil, E. M., . & Annemans, L. (2020). Methodology of the health economic evaluation of the Feel4Diabetes-study. BMC endocrine disorders, 20(1), 1-11.; Vargas-Uricoechea, H., & Casas-Figueroa, L. Á. (2015). An epidemiologic analysis of diabetes in Colombia. Annals of global health, 81(6), 742-753.; Rasmussen, L., Wettermark, B., Steinke, D., & Pottegård, A. (2022). Core concepts in pharmacoepidemiology: Measures of drug utilization based on individual‐level drug dispensing data. Pharmacoepidemiology and drug safety, 31(10), 1015-1026.; Carver, N., Jamal, Z., & Anderson, A. M. D. (2023). Drug Utilization Review. StatPearls [Internet].; Strom, B. (2020). What is pharmacoepidemiology? In B. Strom, S. E. Kimmel & S. Hennessy (Eds.), Pharmacoepidemiology. Chichester: Ed John Willey & sons Ltd.; Elseviers, M., Wettermark, B., Almarsdóttir, A. B., Andersen, M., Benko, R., Bennie, M., . & Vander Stichele, R. (2016). Drug utilization research: methods and applications. John Wiley & Sons.; Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. The Lancet, 383(9922), 1068-1083.; Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., . & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences, 21(17), 6275.; Montero, M. D. L. A. L., Moldón, Y. R., Duque, R. R., & Escofet, S. N. (2020). Mecanismos moleculares de la secreción de insulina. Correo Científico Médico de Holguín, 24(2), 782-798.; World Health Organization. (2021). Improving diabetes outcomes for all, a hundred years on from the discovery of insulin: report of the Global Diabetes Summit.; Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., . & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes; Bommer, C., Sagalova, V., Heesemann, E., Manne-Goehler, J., Atun, R., Bärnighausen, T., . & Vollmer, S. (2018). Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes care, 41(5), 963-970.; Diabetes tipo 2: principios de patogénesis y terapia.Michael Stumvoll, Barry J. Goldstein, Timon W. van Haeften; Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., . & Mirza, W. (2017). Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Frontiers in endocrinology, 8, 6.; Base de datos Invima. [Internet].; Feingold, K. R. (2022). Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. Endotext [Internet].; Xu, Y., Fu, E. L., Clase, C. M., Mazhar, F., Jardine, M. J., & Carrero, J. J. (2022). GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes. Kidney International, 101(2), 360-368.; Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016). Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clinical pharmacokinetics, 55, 657-672.; Fontalvo, J. E. R., Arnedo, R. D., Raad, M., Pájaro, N., Guerrero, J. C., Oviedo, A. V., . & Franco, E. A. (2021). Agonistas del receptor Glp-1: Desde su efecto fisiológico en el sistema incretina hasta du rol en enfermedad renal diabetica. Archivos de medicina, 17(2), 2.; Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2023 Jan 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/; Hall, S., Isaacs, D., & Clements, J. N. (2018). Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clinical pharmacokinetics, 57, 1529-1538.; Overgaard, R. V., Navarria, A., Ingwersen, S. H., Bækdal, T. A., & Kildemoes, R. J. (2021). Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials. Clinical Pharmacokinetics, 60, 1335-1348.; Smith LL, Mosley JF 2nd, Parke C, Brown J, Barris LS, Phan LD. Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist. P T. 2016 Jun;41(6):357-60. PMID: 27313432; PMCID: PMC4894510.; de Diagnóstico, D. L. Ficha técnica o resumen de las características del producto.Dulaglutida. https://ec.europa.eu/health/documents/community-register/2014/20141121130063/anx_130063_es.pdf; Cirincione B, Mager DE. Population pharmacokinetics of exenatide. Br J Clin Pharmacol. 2017 Mar;83(3):517-526. doi:10.1111/bcp.13135. Epub 2016 Nov 16. PMID: 27650681; PMCID: PMC5306477; Barrientos‐Pérez, M., Hsia, D. S., Sloan, L., Nell, H., Mungur, O., Hovsepian, L., . & Niemoeller, E. (2022). A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes. Pediatric Diabetes, 23(6), 641-648.; Mulvihill, E. E., & Drucker, D. J. (2014). Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocrine reviews, 35(6), 992-1019.; Kasina SVSK, Baradhi KM. Inhibidores de la dipeptidil peptidasa IV (DPP IV). [Actualizado el 22 de mayo de 2023]. En: StatPearls [Internet]. Isla del Tesoro (FL): StatPearls Publishing; 2023 enero-. Disponible en: https://www-ncbi-nlm-nih-gov.translate.goog/books/NBK542331/?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=sc; Subbarayan, S., & Kipnes, M. (2011). Sitagliptin: a review. Expert opinion on pharmacotherapy, 12(10), 1613-1622.; He, Y. L. (2012). Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clinical pharmacokinetics, 51, 147-162.; Boulton, D. W. (2017). Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor. Clinical pharmacokinetics, 56(1), 11-24.; Guedes, E. P., Hohl, A., De Melo, T. G., & Lauand, F. (2013). Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetology & metabolic syndrome, 5(1), 1-7.; Pérez López, G., González Albarrán, O., & Cano Megías, M. (2010). Inhibidores del cotransportador sodio-glucosa tipo 2 (SGLT2): de la glucosuria renal familiar al tratamiento de la diabetes mellitus tipo 2. Nefrología (Madrid), 30(6), 618-625.; Padda IS, Mahtani AU, Parmar M. Inhibidores de la proteína 2 de transporte de sodio-glucosa (SGLT2). [Actualizado el 3 de junio de 2023]. En: StatPearls [Internet]. Isla del Tesoro (FL): StatPearls Publishing; 2023 enero.; Xu, B., Li, S., Kang, B., & Zhou, J. (2022). The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovascular diabetology, 21(1), 83.; Kasichayanula, S., Liu, X., LaCreta, F., Griffen, S. C., & Boulton, D. W. (2014). Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clinical pharmacokinetics, 53, 17-27.; Scheen, A. J. (2014). Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clinical pharmacokinetics, 53, 213-225.; Devineni, D., & Polidori, D. (2015). Clinical pharmacokinetic, pharmacodynamic, and drug–drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clinical pharmacokinetics, 54, 1027-1041.; Li, Y., Nucci, G., Yamamoto, Y., Fediuk, D. J., & Sahasrabudhe, V. (2021). Pharmacokinetics and pharmacodynamics of ertugliflozin in healthy Japanese and western subjects. Clinical Pharmacology in Drug Development, 10(7), 765-776.; Costello RA, Nicolas S, Shivkumar A. Sulfonylureas. [Updated 2023 Jul 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513225/; Aschner M, P., Muñoz V, Ó. M., Girón C, D., García M, O. M., Fernández Á, D. G., Casas, L. Á., . & Bustamante S, Á. A. (2017). Guía colombiana de práctica clínica para el tratamiento de la diabetes mellitus tipo 2: falla al tratamiento inicial. Universitas Médica, 58(4).; Lv, W., Wang, X., Xu, Q., & Lu, W. (2020). Mechanisms and characteristics of sulfonylureas and glinides. Current Topics in Medicinal Chemistry, 20(1), 37-56.; Contreras, F., Romero, B., Suárez, N., González, M., Fouillioux, C., Guevara, E., . & Velasco, M. (2002). Receptores Sur y Sulfonilureas en el tratamiento de la Diabetes Mellitus Tipo 2. Archivos Venezolanos de Farmacología y Terapéutica, 21(2), 148-155.; Joshi, S. R., Parikh, R. M., & Das, A. K. (2007). Insulin-history, biochemistry, physiology and pharmacology. Journal-association of physicians of India, 55(L), 19.; Mathieu, C., Martens, P. J., & Vangoitsenhoven, R. (2021). One hundred years of insulin therapy. Nature Reviews Endocrinology, 17(12), 715-725.; Haahr, H., Fita, E. G., & Heise, T. (2017). A review of insulin degludec/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use. Clinical pharmacokinetics, 56, 339-354.; Lindholm, A., & Jacobsen, L. V. (2001). Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clinical pharmacokinetics, 40, 641-659.; Wang, F., Carabino, J. M., & Vergara, C. M. (2003). Insulin glargine: a systematic review of a long-acting insulin analogue. Clinical therapeutics, 25(6), 1541-1577.; Becker, R. H., & Frick, A. D. (2008). Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clinical pharmacokinetics, 47, 7-20.; Keating, G. M. (2012). Insulin detemir: a review of its use in the management of diabetes mellitus. Drugs, 72, 2255-2287.; Holcombe, J. H., Zalani, S., Arora, V. K., Mast, C. J., & Lispro in Adolescents Study Group. (2002). Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clinical therapeutics, 24(4), 629-638.; Lv, Z., & Guo, Y. (2020). Metformin and its benefits for various diseases. Frontiers in endocrinology, 11, 191.; LaMoia, T. E., & Shulman, G. I. (2021). Cellular and molecular mechanisms of metformin action. Endocrine reviews, 42(1), 77-96.; LEY NUMERO 100 DE 1993. Por la cual se crea el sistema de seguridad social integral y se dictan otras disposiciones. 23 de diciembre de 1993. De https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/ley-100-de-1993.pdf; (Ministerio de Salud y Protección Social. (2017). Aseguramiento al Sistema General de Seguridad Social.). De https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VP/DOA/RL/cartillas-de-aseguramiento-al-sistema-general-de-seguridad-social-en-salud.pdf; Granger, C., Ramos-Forero, J. E., Melo-Becerra, L. A., & Silva-Samudio, G. T. (2023). Financiamiento del Sistema de Salud en Colombia: Fuentes y usos. Borradores de Economía; No. 1233.; Salud, P. E. (2018). Estructura del gasto en Salud Pública en Colombia. Ministerio de Salud y Protección Social, 17, 1-46.; Zea, R., Humberto, J., & Cortés, O. L. Z. (2021). Desafíos de la gobernanza en salud en Colombia: Una mirada con actores del sistema de salud. Documento de trabajo, Medellín, Grupo de Economía de la Salud (ges), Universidad de Antioquia.); Osorio Vargas, E. L., Quiroga Rodriguez, K. L., & Delgado Piraquive, L. Y. (2021). Antecedentes y análisis de los impactos de la Ley de presupuestos máximos para las tecnologías No cubiertos en el Plan de Beneficios en Salud.; Ministerio de Salud y Protección Social. Sistema Integral de Información de la Protección Social – SISPRO. Gov.co. Recuperado el 20 de enero de 2024, de https://www.minsalud.gov.co/rea%20de%20trabajo%20colaborativo/Sistemas%20de%20Informaci%C3%B3n/DOC%2002%20MPS%20%20MODELO%20CONCEPTUAL%20DEL%20SGD%2003-04-07%20V3%200%20(2).pdf; LEY NÚMERO 1122 DE 2007. Por la cual se hacen algunas modificaciones en el Sistema General de Seguridad Social en Salud y se dictan otras disposiciones. 9 de enero del 2007. De https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/ley-1122-de-2007.pdf.; Ministerio de Salud y Protección Social. Sistema Integral de Información de la Protección Social SISPRO Componente salud. Recuperado el 20 de enero del 2024.De https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/OT/5%20SisproSalud_Gestion%20Conocimiento_MSPS.pdf.; Ministerio de Salud y Protección Social.Sistema Integrado de Información de la Protección Social en Colombia, tercera generación. SISPRO 3G Recuperado el 20 de enero del 2024. De https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/sispro-3G.pdf; Noguera, J. A., Larrahondo, Y. F. C., Caicedo, A. E. M., Cuellar, G. V. O., & Aguirre, L. F. G. (2021). Sistemas de información de salud en Colombia. Interdisciplinary Journal of Epidemiology and Public Health, 4(1).; LEY 9 DE 1979 (enero 24). Por la cual se dictan Medidas Sanitarias. Diario Oficial No. 35308. 16 de julio de 1979. De //https://www.minsalud.gov.co/Normatividad_Nuevo/LEY%200009%20DE%201979.pdf; Ley 715 de diciembre 21 de 2001. se dictan otras disposiciones para organizar la prestación de los servicios de educación y salud, entre otros. 21 de diciembre del 2001.De https://www.mineducacion.gov.co/1621/articles-86098_archivo_pdf.pdf; LEY ESTATUTARIA 1751 DE 2015. Por medio de la cual se regula el derecho fundamental a la salud y se dictan otras disposiciones. Diario Oficial No. 49.427 de 16 de febrero de 2015. De https://www.cancilleria.gov.co/sites/default/files/Normograma/docs/pdf/ley_1751_2015.pdf.; SISPRO - Sistema integrado de información de la protección social. (s/f). Gov.Co. Recuperado el 20 de enero de 2024, de https://www.sispro.gov.co/Pages/Home.aspx.; DECRETO 2699 DE 2007. Por el cual se establecen algunas normas relacionadas con el Sistema General de Seguridad Social en Salud y se dictan otras disposiciones. Julio 13 2007. De https://www.funcionpublica.gov.co/eva/gestornormativo/norma.php?i=166446; Quiénes somos - Cuenta de Alto Costo. (2019, octubre 7). Cuenta de Alto Costo - Fondo Colombiano de Cuentas de Alto Costo, organismo técnico no gubernamental del Sistema General de Seguridad Social en Salud de Colombia creado mediante el Decreto 2699 de 2007; Cuenta de Alto Costo. https://cuentadealtocosto.org/quienes-somos/; Alto Costo, C. Criterios para identificar patologías de alto costo en Colombia. Recuperado de:https://cuentadealtocosto. org/site/images/Publicaciones/ALTO_COSTO_FINAL_PUBLICACION_13_02_14. pdf.; Celentano, D. D., Mhs, S., & Szklo, M. (2019). Gordis. Epidemiología. Elsevier.; Fletcher, R. H., Fletcher, S. W., & Wagner, E. H. (1991). Epidemiología clínica. In Epidemiologia clínica (pp. 312-312).; León-Álvarez, A. L., Betancur-Gómez, J. I., Jaimes-Barragán, F., & Grisales-Romero, H. (2016). Ronda clínica y epidemiológica. Series de tiempo. Iatreia, 29(3), 373-381.; Bello, L. D., & Martínez, S. (2007). Una metodología de series de tiempo para el área de la salud; caso práctico. Revista Facultad Nacional de Salud Pública, 25(2), 118-122.; Guerrero, V. M. G. (2003). Análisis estadístico de series de tiempo económicas. Thomson.; González Casimiro, M. P. (2009). Análisis de series temporales: Modelos ARIMA.; A. Sommet, Antoine Pariente. Methods in pharmacoepidemiology. Thérapie, 2019, 74 (2), pp.187-197. ff10.1016/j.therap.2018.11.015ff. ffhal-0316369; Ruslanivna, Huk Karina1; Yaroslavivna, Bespalova Olena2,. Pharmacoeconomic Aspects of Pharmaceutical Ethics. Biomedical and Biotechnology Research Journal (BBRJ) 6(3):p 302-310, Jul–Sep 2022. %7C DOI:10.4103/bbrj.bbrj_115_22; Aschner, P. (2010). Epidemiología de la diabetes en Colombia. Avances en diabetología, 26(2), 95-100.; Leiva, A. M., Martínez, M. A., Cristi-Montero, C., Salas, C., Ramírez-Campillo, R., Díaz Martínez, X., . & Celis-Morales, C. (2017). El sedentarismo se asocia a un incremento de factores de riesgo cardiovascular y metabólicos independiente de los niveles de actividad física. Revista médica de Chile, 145(4), 458-467.; Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., . & Brauer, M. (2023). Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet.; Chacko, E., & Signore, C. (2020). Five evidence-based lifestyle habits people with diabetes can use. Clinical Diabetes, 38(3), 273-284.; Rooney, M. R., Rawlings, A. M., Pankow, J. S., Tcheugui, J. B. E., Coresh, J., Sharrett, A. R., & Selvin, E. (2021). Risk of progression to diabetes among older adults with prediabetes. JAMA internal medicine, 181(4), 511-519.; Wang, T., Zhao, Z., Wang, G., Li, Q., Xu, Y., Li, M., . & Wang, W. (2021). Age-related disparities in diabetes risk attributable to modifiable risk factor profiles in Chinese adults: a nationwide, population-based, cohort study. The Lancet Healthy Longevity, 2(10), e618-e628.; Social, M. D. (2013). Envejecimiento demográfico, Colombia 1951-2020 Dinámica demográfica y estructuras poblacionales.; Romero-Prieto, J. E., & Meisel-Roca, A. (2019). Análisis demográfico de la Violencia en Colombia. Cuadernos de Historia Económica; No. 50.; Índice de envejecimiento activo en Colombia: análisis basado en la Encuesta Nacional de Salud, Bienestar y Envejecimiento (SABE Colombia 2015); Sánchez Amorocho, C. E. (2017). Desigualdades en salud entre regímenes subsidiado y contributivo del Sistema General de Seguridad Social en Salud en Colombia [master’s thesis]. Bogotá DC: Universidad de los Andes.; Bantie GM, Wondaye AA, Arike EB, Melaku MT, Ejigu ST, Lule A, Lingerew WM, Tamirat KS. Prevalence of undiagnosed diabetes mellitus and associated factors among adult residents of Bahir Dar city, northwest Ethiopia: a community-based cross-sectional study. BMJ Open. 2019 Oct 31;9(10):e030158. doi:10.1136/bmjopen-2019-030158. PMID: 31676649; PMCID: PMC6830649.; Liu, J., Stella, S. Y., Russo, R., Mayer, V. L., Wen, M., & Li, Y. (2023). Trends and disparities in diabetes and prediabetes among adults in the United States, 1999–2018. Public Health, 214, 163-170.; Carrillo-Larco, R. M., Bracco, P. A., Bernabe-Ortiz, A., Lazo-Porras, M., Zafra-Tanaka, J. H., Tenorio-Mucha, J., . & Beran, D. (2023). Diabetes Management in Latin America. In The Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues (pp. 285-308). Cham: Springer International Publishing.; Wang, G. X., Gauthier, R., Gunter, K. E., Johnson, L., Zhu, M., Wan, W., . & Chin, M. H. (2023). Improving diabetes care through population health innovations and payments: lessons from Western Maryland. Journal of General Internal Medicine, 38(Suppl 1), 48-55.; Iregui-Bohórquez, A. M., Melo-Becerra, L. A., Pinilla-Alarcón, D. E., & Ramírez-Giraldo, M. T. (2023). Evolución y carga financiera de las Enfermedades Crónicas no Transmisibles en Colombia: 2010-2021. Borradores de Economía; No. 1234.; Perfil de carga de enfermedad por diabetes 2023: Colombia. Recuperada en Iregui-Bohórquez, A. M., Melo-Becerra, L. A., Pinilla-Alarcón, D. E., & Ramírez-Giraldo, M. T. (2023). Evolución y carga financiera de las Enfermedades Crónicas no Transmisibles en Colombia: 2010-2021. Borradores de Economía; No. 1234.; Harding, J. L., Oviedo, S. A., Ali, M. K., Ofotokun, I., Gander, J. C., Patel, S. A., . & Patzer, R. E. (2023). The bidirectional association between diabetes and long-COVID-19–A systematic review. Diabetes Research and Clinical Practice, 195, 110202.; Nowakowska, M., Zghebi, S. S., Ashcroft, D. M., Buchan, I., Chew-Graham, C., Holt, T., Mallen, C., Van Marwijk, H., Peek, N., Perera-Salazar, R., Reeves, D., Rutter, M. K., Weng, S. F., Qureshi, N., Mamas, M. A., & Kontopantelis, E. (2019). The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Medicine, 17(1), 145. https://doi.org/10.1186/s12916-019-1373-y. Erratum in: BMC Med. 2020 Jan 25;18(1):22. PMID: 31345214; PMCID: PMC6659216.; Liu, J., Liu, M., Chai, Z., Li, C., Wang, Y., Shen, M., . & Zhang, L. (2023). Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030. The Lancet Regional Health–Western Pacific, 33.; Núñez, J. (2023). Logros en equidad del sistema de salud y la reforma en Colombia.; https://repositorio.unal.edu.co/handle/unal/86407; Universidad Nacional de Colombia; Repositorio Institucional Universidad Nacional de Colombia; https://repositorio.unal.edu.co/
-
7
Autoren: et al.
Quelle: ISSN: 1424-7860 ; Swiss Medical Weekly, vol. 148 (2018) w14649.
Schlagwörter: info:eu-repo/classification/ddc/174.957, info:eu-repo/classification/ddc/616.07, info:eu-repo/classification/ddc/616, info:eu-repo/classification/ddc/618.97, Antiviral Agents / economics, Antiviral Agents / therapeutic use, Consumer Advocacy / economics, Consumer Organizations / economics, Drug Costs / statistics & numerical data, Health Services Accessibility, Hepacivirus / drug effects, Hepacivirus / isolation & purification, Hepatitis C, Chronic / drug therapy, Humans, Medically Uninsured, Switzerland, Vulnerable Populations
Relation: info:eu-repo/semantics/altIdentifier/pmid/30141526; unige:109285
Verfügbarkeit: https://archive-ouverte.unige.ch/unige:109285
-
8
Autoren: et al.
Weitere Verfasser: et al.
Quelle: ISSN: 0013-7006 ; L'Encéphale ; https://hal.science/hal-04490736 ; L'Encéphale, 2023, ⟨10.1016/j.encep.2023.09.007⟩.
Schlagwörter: Étude de coût, Psychiatry, Psychiatrie, Esketamine, Cost-effectiveness analysis, MESH: Adult, MESH: Antidepressive Agents / economics, MESH: Excitatory Amino Acid Antagonists / economics, MESH: Excitatory Amino Acid Antagonists / therapeutic use, MESH: Female, MESH: France, MESH: Humans, MESH: Ketamine* / economics, MESH: Ketamine* / therapeutic use, MESH: Male, MESH: Middle Aged, MESH: Psychiatry / economics, MESH: Antidepressive Agents / therapeutic use, MESH: Depressive Disorder, Major / drug therapy, Major / economics, Major / psychology, Treatment-Resistant* / drug therapy, Treatment-Resistant* / economics, Treatment-Resistant* / psychology, MESH: Drug Costs / statistics & numerical data, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Relation: info:eu-repo/semantics/altIdentifier/pmid/38040510; PUBMED: 38040510
-
9
Autoren: et al.
Quelle: The Journal of Rheumatology. 36:76-81
Schlagwörter: Adult, Male, Hospital Costs - Statistics & Numerical Data, Pneumonia - Economics - Epidemiology - Etiology, Lupus Nephritis - Drug Therapy - Economics - Epidemiology, Infections, Cyclophosphamide - Administration & Dosage - Adverse Effects - Economics, Drug Costs, Immunocompromised Host, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Azathioprine, Humans, Hospital Costs, Infection - Economics - Epidemiology - Etiology, Cyclophosphamide, Drug Costs - Statistics & Numerical Data, Incidence, Mycophenolic Acid - Administration & Dosage - Adverse Effects - Analogs & Derivatives - Economics, Pneumonia, Middle Aged, Mycophenolic Acid, Lupus Nephritis, 3. Good health, Immunosuppressive Agents - Administration & Dosage - Adverse Effects - Economics, Female, Azathioprine - Administration & Dosage - Adverse Effects - Economics, Immunosuppressive Agents
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/19004041
http://www.jrheum.org/content/36/1/76.short
https://www.ncbi.nlm.nih.gov/pubmed/19004041
https://europepmc.org/article/MED/19004041
https://www.jrheum.org/content/jrheum/36/1/76.full.pdf
https://hub.hku.hk/handle/10722/163223
https://www.jrheum.org/content/36/1/76
http://hdl.handle.net/10722/163223 -
10
Autoren: et al.
Quelle: Eur J Cardiovasc Prev Rehabil. 12(1):29-36
Schlagwörter: Medical and Health Sciences, Medicin och hälsovetenskap, Cerebrovascular Accident/*prevention & control, Coronary Arteriosclerosis/*prevention & control, Cost-Benefit Analysis, Drug Costs/*statistics & numerical data, Heptanoic Acids/*economics/*therapeutic use, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/*economics/*therapeutic use, Hypertension/*complications/*drug therapy, Placebos, Pyrroles/*economics/*therapeutic use, Treatment Outcome
Zugangs-URL: https://gup.ub.gu.se/publication/56037
-
11
Autoren: et al.
Quelle: Journal of Neurology, Vol. 249, No 6 (2002) pp. 759-766
Schlagwörter: Male, Parkinson Disease/drug therapy/physiopathology/*surgery, Health Care Costs/*statistics & numerical data, Cost-Benefit Analysis, Health Status, Electric Stimulation Therapy/economics/*statistics & numerical data, Electric Stimulation Therapy, Drug Costs, Delivery of Health Care/*utilization, Antiparkinson Agents, 03 medical and health sciences, 0302 clinical medicine, Subthalamic Nucleus, Germany, Humans, Aged, Drug Costs/statistics & numerical data, Cost-Benefit Analysis/statistics & numerical data, Parkinson Disease, Health Care Costs, Middle Aged, Antiparkinson Agents/administration & dosage/adverse effects/*economics, 3. Good health, Subthalamic Nucleus/physiology/*surgery, Female, Delivery of Health Care
Dateibeschreibung: application/pdf
Zugangs-URL: https://archive-ouverte.unige.ch/unige:95877/ATTACHMENT01
https://pubmed.ncbi.nlm.nih.gov/12111311
https://archive-ouverte.unige.ch/unige:95877
https://europepmc.org/article/MED/12111311
https://archive-ouverte.unige.ch/unige:95877/ATTACHMENT01
https://pubmed.ncbi.nlm.nih.gov/12111311/
https://link.springer.com/article/10.1007%2Fs00415-002-0711-7
http://www.ncbi.nlm.nih.gov/pubmed/12111311
https://archive-ouverte.unige.ch/unige:95877
https://archive-ouverte.unige.ch/unige:95877
https://doi.org/10.1007/s00415-002-0711-7 -
12
Autoren: et al.
Quelle: Läkartidningen. 109(29-31):1350
-
13
Autoren: et al.
Quelle: ISSN: 0036-7672 ; Schweizerische medizinische Wochenschrift, vol. 144 (2014) w13925.
Schlagwörter: info:eu-repo/classification/ddc/618, Adolescent, Ambulatory Care/economics, Child, Preschool, Community-Acquired Infections/economics, Cost of Illness, Direct Service Costs/statistics & numerical data, Drug Costs/statistics & numerical data, Female, Health Resources/economics/utilization, Hospital Costs/statistics & numerical data, Hospitalization/economics, Humans, Infant, Male, Pneumonia/economics, Prospective Studies, Severity of Illness Index, Switzerland
Relation: info:eu-repo/semantics/altIdentifier/pmid/24706389; unige:55140
Verfügbarkeit: https://archive-ouverte.unige.ch/unige:55140
-
14
Autoren: et al.
Quelle: Nordic Journal of Psychiatry. 62(2):114
-
15
Autoren:
Schlagwörter: Adolescent, Humans, Germany, Body Mass Index, Child, Age Distribution, Socioeconomic Factors, Interviews as Topic, Sex Distribution, Poisson Distribution, Costs and Cost Analysis, Drug Costs*/statistics & numerical data, Drug Utilization*/standards, Drug Utilization*/statistics & numerical data, Obesity/drug therapy, Obesity/prevention & control, Pharmaceutical Preparations/economics, Pharmaceutical Preparations/supply & distribution, Physical Examination, Physician's Practice Patterns/standards, Physician's Practice Patterns/statistics & numerical data, Transients and Migrants/classification, 610 Medizin, ddc:610
Dateibeschreibung: application/pdf
Relation: http://edoc.rki.de/oa/articles/reUh9wJuNfaOk/PDF/23eJvigozzPOM.pdf; http://edoc.rki.de/176904/1050; http://dx.doi.org/10.25646/975
-
16
Autoren: et al.
Quelle: Parkinson-journalen. 9(4):20
-
17
Autoren:
Quelle: Drugs. 65(5):661-694
-
18
Autoren: et al.
Quelle: Swiss Medical Weekly, Vol 142, Iss 1112 (2012)
Swiss Medical Weekly, Vol. 142 (2012) P. w13536
Swiss medical weeklySchlagwörter: Length of Stay/economics, Male, cost comparison, hospital costs, Enoxaparin/economics/therapeutic use, Drug Costs, Anticoagulants/economics/therapeutic use, 03 medical and health sciences, NSTEMI acute coronary events, 0302 clinical medicine, Polysaccharides, Hospital Costs/statistics & numerical data, Humans, Acute Coronary Syndrome, Enoxaparin, Hospital Costs, Polysaccharides/economics/therapeutic use, ddc:613, Aged, Retrospective Studies, ddc:616, anticoagulation therapy, Acute Coronary Syndrome/drug therapy/economics, Drug Costs/statistics & numerical data, Anticoagulants, Length of Stay, 3. Good health, Treatment Outcome, Fondaparinux, Factor X, Costs and Cost Analysis, Medicine, Female, Switzerland, Follow-Up Studies
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/22430741
https://doaj.org/article/86243d96e392496eb6be60d05372da0e
http://doi.emh.ch/smw.2012.13536
https://doi.emh.ch/smw.2012.13536
https://archive-ouverte.unige.ch/unige:31879
http://www.ncbi.nlm.nih.gov/pubmed/22430741
https://smw.ch/en/article/doi/smw.2012.13536/
https://core.ac.uk/display/60872796
https://archive-ouverte.unige.ch/unige:31879
https://doi.org/10.4414/smw.2012.13536
https://archive-ouverte.unige.ch/unige:31879 -
19
Autoren: et al.
Quelle: ISSN: 0036-7672 ; Schweizerische medizinische Wochenschrift, vol. 142 (2012) w13536.
Schlagwörter: info:eu-repo/classification/ddc/613, info:eu-repo/classification/ddc/616, Acute Coronary Syndrome/drug therapy/economics, Aged, Anticoagulants/economics/therapeutic use, Costs and Cost Analysis, Drug Costs/statistics & numerical data, Enoxaparin/economics/therapeutic use, Factor X, Female, Follow-Up Studies, Hospital Costs/statistics & numerical data, Humans, Length of Stay/economics, Male, Polysaccharides/economics/therapeutic use, Retrospective Studies, Switzerland, Treatment Outcome
Relation: info:eu-repo/semantics/altIdentifier/pmid/22430741; unige:31879
Verfügbarkeit: https://archive-ouverte.unige.ch/unige:31879
-
20
Autoren:
Schlagwörter: the phased therapy, pharmacoeconomics, rational therapy, hospital departments, parenteral and oral drug prescription, pharmaceutical forms, Economics, Pharmaceutical, Drug Costs--statistics & numerical data, Dosage Forms, Infusions, Parenteral--economics, Administration, Oral
Dateibeschreibung: application/pdf
Relation: Curierul medical; http://repository.usmf.md/handle/20.500.12710/8358
Nájsť tento článok vo Web of Science 
Full Text Finder 
Full Text